President Biden’s request for fiscal 2024 funding includes $7.2 billion for the FDA, some of which is earmarked for research in the areas of opioid and other drug abuse, rare neurodegenerative diseases and cancer.

The administration’s FDA budget request, announced last week, is approximately 10 percent more than what the agency actually received in 2023 funding but still $1.2 billion below Biden’s fiscal 2023 request of $8.4 billion.

The administration’s detailed budget request is not due out until early this week, but the FDA released its own summary highlighting several agency activities for additional funding.

They include an extra $23 million to support broader development of opioid overdose reversal treatments and treatments for substance use disorders, and to enhance regulatory oversight, expand compliance, enforcement and laboratory support.

The request also includes $2.5 million to implement the Accelerating Access to Critical Therapies for Amyotrophic Lateral Sclerosis (ACT for ALS) program to foster development of treatments for ALS and other rare neurodegenerative diseases. The additional funding would “strengthen the agency’s ability to issue new grants and contracts, hire dedicated expert staff and allow the FDA to facilitate access to investigational therapies and medical devices for neurodegenerative diseases,” the agency said.

The administration is also requesting $50 million to help reignite the Cancer Moonshot. This funding would expand resources and collaborations for new diagnostic and therapeutic products to treat rare cancers and other efforts to address cancer morbidity and mortality, the agency said.

In addition, the extra funding would advance efforts to improve evidence generation for underrepresented subgroups in oncology clinical trials, support pragmatic and decentralized trials, and advance sources of evidence through patient-generated data, learnings and real-world evidence, the agency said.